Where does Eris Lifesciences make most of its revenue?

India: 92% of revenue by region in fiscal year 2025, followed by outside India (8%).

What companies are similar to Eris Lifesciences?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Granules India Limited (GRANULES.NS), Caplin Point Laboratories Limited (CAPLIPOINT.NS), Pfizer Limited (PFIZER.NS), Alembic Pharmaceuticals Limited (APLLTD.BO).

Eris Lifesciences Limited (ERIS.NS) Stock

About Eris Lifesciences Limited

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women'...

At a glance

In Q2 2026 (the quarter ended September 30, 2025) revenue was 7.90 billion INR, up 6.9% from a year before. India was its largest region in fiscal year 2025, with 92% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.